Parvis Provides Update on Convertible Debenture Financing 
Theralase(R) Announces $5 Million Brokered LIFE Offering 
CEO.CA’s Inside the Boardroom: Independence Gold Hits Three New Gold Discoveries With More Assays Pending 
Mobile-health Network Solutions Advances AI-Powered Lab Data Analysis to Transform Clinical Decision-Making 
Aitenders Technologies Receives Final Approval from CSE and Commences Trading CRN Honors Zenoss With 5-Star Rating in 2022 Partner Program Guide
Zenoss Partner Network Recognized for Its Accelerated Growth and Streamlined Enablement AUSTIN, Texas–(BUSINESS WIRE)–#AIOps–Zenoss Inc.,…
SkyWater Florida Achieves ISO 9001:2015 Quality Management System Certification
Major step for production readiness of domestic heterogeneous integration solutions BLOOMINGTON, Minn.–(BUSINESS WIRE)–SkyWater Technology (NASDAQ:…
Polygon and Credix Partner with Centre to Support Verite for Decentralized Identity in Web3
Polygon and Credix join a growing list of launch partners supporting Centre’s decentralized identity protocol…
Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
Abivertinib is a novel oral small molecule tyrosine kinase inhibitor that selectively targets both mutant…
Assertio Holdings, Inc. Partners with BlinkRx to Support Healthcare Providers and Patients Utilizing Otrexup® (methotrexate) with a Unique Patient Access Solution
Collaboration Eases Patient Access to Therapy LAKE FOREST, Ill., March 31, 2022 (GLOBE NEWSWIRE) —…
HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-release Ketamine (KET01) Study
Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in…
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
– 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4…
Acer Therapeutics Regains Compliance with Nasdaq Listing Standard
NEWTON, Mass., March 31, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
Celsion Corporation Reports 2021 Financial Results and Provides Business Update
Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins…
Shockwave Medical Announces Global Launch of New Peripheral Intravascular Lithotripsy Catheter
Shockwave M5+ IVL Catheter Broadens Options for Treatment of Peripheral Arteries SANTA CLARA, Calif., March…
Ring Therapeutics Announces Publication Highlighting the Immune Favorability of Commensal Anelloviruses
– First description of new, comprehensive anellovirus antibody analysis tool, AnelloScan – – Cross-sectional study supports…
Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD
ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved, expected to receive 12 years of marketing exclusivity ISELIN,…
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting
REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a…
Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform…
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO)…
VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian…
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association
Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality…
Portage Biotech Provides Update on Clinical-Stage and Development Programs
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued…
Science 37® Adds Acclaimed Researcher and Oncologist, Dr. Shaalan Beg to Bolster Therapeutic Depth
Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial…
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split
DALLAS, Texas, March 31, 2022 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)…